Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model.

Xue-Feng LiuXiao-Dong ZhuLong-Hai FengXiao-Long LiBin XuKang-Shuai LiNan XiaoMing LeiHui-Chuan SunZhao-You Tang

Published in: Experimental hematology & oncology (2022)

Regular physical activity was associated with improved outcomes in unresectable HCC receiving combined lenvatinib plus anti-PD-1 therapy. Physical activity may improve therapeutic efficacy by reprograming the tumor microenvironment from an immunosuppressive to immunostimulatory phenotype.

Keyphrases

physical activity
mouse model
body mass index
locally advanced
liver metastases
sleep quality
squamous cell carcinoma
type diabetes
adipose tissue
mesenchymal stem cells
depressive symptoms
weight loss
replacement therapy